INVO Bioscience, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (Nasdaq: INVO) on January 5, 2023, covering events occurring on December 29, 2022, and January 4, 2023. The filing details the entry into material definitive agreements involving debt financing and the unregistered sale of equity securities.
Key Financial Metrics and Obligations
- Convertible Notes (Private Placement): The Company entered into agreements to sell unsecured convertible notes with an aggregate original principal amount of $275,000.
- Warrants (Private Placement): Issued 5-year warrants to purchase 275,000 shares of common stock at an exercise price of $1.00 per share.
- Related Party Loan: Entered into a demand promissory note with JAG Multi Investments LLC (a related party to the CFO) for $100,000.
- Related Party Warrant: Issued a warrant to JAG Multi Investments LLC to purchase 350,000 shares at $0.50 per share.
- Debt Extension: Extended the payment date for existing demand promissory notes totaling $400,000 (of which $350,000 is currently demandable) to March 31, 2023.
- Interest Rates: New convertible notes accrue interest at 10% per annum. The related party note is interest-free until January 31, 2023, then accrues 10% annually.
- Use of Proceeds: Proceeds from the private placement are designated for working capital and general corporate purposes.
Material Changes and Terms
The filing reports the creation of new direct financial obligations and the issuance of unregistered equity securities. Key terms include:
- Conversion Mechanics: The $275,000 notes are convertible at a fixed price of $0.50 per share, subject to anti-dilution adjustments. Holders may convert into shares issued in a subsequent equity financing at 80% of the new issue price.
- Ownership Limitation: Conversion is restricted if the holder would beneficially own more than 9.99% of outstanding shares.
- Prepayment: The Company may prepay the convertible notes at 100% of principal plus accrued interest.
- Related Party Terms: The $100,000 related party note is callable with 10 days' notice starting March 31, 2023, and requires a 10% financing fee at maturity.
Outlook, Risks, and Contingencies
The filing does not provide specific forward-looking guidance, revenue projections, or management commentary on future performance. However, it highlights the following risks and contingencies:
- Liquidity Needs: The immediate issuance of debt and extension of existing obligations suggests a need for working capital.
- Dilution Risk: The issuance of warrants and convertible notes creates potential dilution for existing shareholders, particularly given the low conversion price ($0.50) relative to the warrant exercise price ($1.00) in the private placement.
- Default Triggers: The notes contain customary triggering events, including failure to make payments or bankruptcy, which could allow holders to demand immediate cash redemption.
- Registration Rights: The Company agreed to include shares underlying the notes and warrants in future registration statements, subject to SEC Rule 415 limitations.
Investor Verification Checklist
- Verify the current cash balance and liquidity position to assess the ability to service the new $275,000 debt and the extended $400,000 related party obligation.
- Confirm the exact number of shares outstanding to calculate the potential dilution impact of the 625,000 new warrants and the convertible notes.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and the Letter Agreement with JAG Multi Investments (Exhibit 4.1) for additional covenants.
- Monitor the Company's ability to raise a "Subsequent Equity Financing" to satisfy the 80% conversion pricing provision.
- Check for any subsequent filings regarding the repayment or conversion of the related party debt by the March 31, 2023 deadline.